194 related articles for article (PubMed ID: 34059075)
21. Are T cells the only HIV-1 reservoir?
Kandathil AJ; Sugawara S; Balagopal A
Retrovirology; 2016 Dec; 13(1):86. PubMed ID: 27998285
[TBL] [Abstract][Full Text] [Related]
22. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
Banga R; Procopio FA; Cavassini M; Perreau M
J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
[TBL] [Abstract][Full Text] [Related]
23. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
24. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.
Chun TW; Engel D; Berrey MM; Shea T; Corey L; Fauci AS
Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8869-73. PubMed ID: 9671771
[TBL] [Abstract][Full Text] [Related]
25. Elimination of HIV-1-Infected Primary T Cell Reservoirs in an In Vitro Model of Latency.
Rawlings SA; Alonzo F; Kozhaya L; Torres VJ; Unutmaz D
PLoS One; 2015; 10(5):e0126917. PubMed ID: 25993666
[TBL] [Abstract][Full Text] [Related]
26. Latent reservoirs of HIV: obstacles to the eradication of virus.
Chun TW; Fauci AS
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):10958-61. PubMed ID: 10500107
[TBL] [Abstract][Full Text] [Related]
27. HIV "shock and kill" therapy: In need of revision.
Abner E; Jordan A
Antiviral Res; 2019 Jun; 166():19-34. PubMed ID: 30914265
[TBL] [Abstract][Full Text] [Related]
28. Single-Cell Profiling of Latently SIV-Infected CD4
Tokarev A; Machmach K; Creegan M; Kim D; Eller MA; Bolton DL
Microbiol Spectr; 2022 Jun; 10(3):e0060422. PubMed ID: 35510859
[TBL] [Abstract][Full Text] [Related]
29. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
Shan L; Siliciano RF
Bioessays; 2013 Jun; 35(6):544-52. PubMed ID: 23613347
[TBL] [Abstract][Full Text] [Related]
30. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
31. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.
Spina CA; Anderson J; Archin NM; Bosque A; Chan J; Famiglietti M; Greene WC; Kashuba A; Lewin SR; Margolis DM; Mau M; Ruelas D; Saleh S; Shirakawa K; Siliciano RF; Singhania A; Soto PC; Terry VH; Verdin E; Woelk C; Wooden S; Xing S; Planelles V
PLoS Pathog; 2013; 9(12):e1003834. PubMed ID: 24385908
[TBL] [Abstract][Full Text] [Related]
32. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.
Painter MM; Zaikos TD; Collins KL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396
[TBL] [Abstract][Full Text] [Related]
33. Redefining the viral reservoirs that prevent HIV-1 eradication.
Eisele E; Siliciano RF
Immunity; 2012 Sep; 37(3):377-88. PubMed ID: 22999944
[TBL] [Abstract][Full Text] [Related]
34. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
35. HIV reservoirs and strategies for eradication.
Smith MZ; Wightman F; Lewin SR
Curr HIV/AIDS Rep; 2012 Mar; 9(1):5-15. PubMed ID: 22249405
[TBL] [Abstract][Full Text] [Related]
36. Modeling the Effects of Latency Reversing Drugs During HIV-1 and SIV Brain Infection with Implications for the "Shock and Kill" Strategy.
Roda WC; Liu S; Power C; Li MY
Bull Math Biol; 2021 Mar; 83(4):39. PubMed ID: 33712983
[TBL] [Abstract][Full Text] [Related]
37. LGIT In Vitro Latency Model in Primary and T Cell Lines to Test HIV-1 Reactivation Compounds.
Jung U; Takahashi M; Rossi JJ; Burnett JC
Methods Mol Biol; 2016; 1354():255-64. PubMed ID: 26714717
[TBL] [Abstract][Full Text] [Related]
38. Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells.
Alvarez-Carbonell D; Garcia-Mesa Y; Milne S; Das B; Dobrowolski C; Rojas R; Karn J
Retrovirology; 2017 Feb; 14(1):9. PubMed ID: 28166799
[TBL] [Abstract][Full Text] [Related]
39. Block and Lock HIV Cure Strategies to Control the Latent Reservoir.
Ahlenstiel CL; Symonds G; Kent SJ; Kelleher AD
Front Cell Infect Microbiol; 2020; 10():424. PubMed ID: 32923412
[TBL] [Abstract][Full Text] [Related]
40. Analysis of HIV latent infection model with multiple infection stages and different drug classes.
Alshorman A; Al-Hosainat N; Jackson T
J Biol Dyn; 2022 Dec; 16(1):713-732. PubMed ID: 36264087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
